We would love to hear your thoughts about our site and services, please take our survey here.
Must really muck up your scheduling of the Olivetti keyboard. Still, keeps you on your toes. You never know when news will drop?
Slow day at Citadel/M&A (delete as appropriate) HQ?
It must get rather crowded on that Olivetti keyboard.
Indeed, outstanding in your field, of parsnips.
I do. I can't imagine anyone being so negative about a stock from the very moment they claim to have bought it. Except for you of course. And Mani. And DocDan. And Axe. Plus Andybe4yo. Then there's Org of course, the delightful if historically-confused Sakura...
I could go on...Too many to name...
"This really is a tough share to be involved with." said the bloke with no involvement whatsoever in the share.
All the lolz today. Mani talking to himself in character as Costas, rinse, repeat.
Yawn.
Wonder where you heard that news Mani?
You're a real man of genius, Professionale, that's why I posted the video below. Reminds me of you.
Https://www.youtube.com/watch?v=AuqFL7UoD-s
Today, we salute you, Professional.
If there's another deal to be had Marsden & Co can pull it off just like the did with the last +$250 million licencing agreement deal -> TFG certainly think so, otherwise they would have replaced him with you. Hé, he.
Hé hé. You funny Professionale.
Staff must be too busy working on a deal or trials to answer your daily calls Mr. Half-a-Million-No-Shares. Some would say that's a promising sign.
Maybe they figured out your name isn't on the share register so aren't taking your calls.
Just a thought.....
"Real people have invested here".
Fanciful, coming from you Costas; contender for fakest investor of the year award.
WPA,
In terms of market, this seems to be where the company have pitched their tent:
* Estimated 3m+ people in US hospitalised annually from 2022 onwards due to severe VRIs
[source: IQVIA market research Q4 2022; Sources: US CDC, HCUP, IQVIA Claims Data, PubMed; data on file]
* 7m immuno-compromised in the US, representing a population at significant risk for severe RVIs [source: American Medical Association
* $50b estimated annual US healthcare costs related to severe VRIs [sources: Hartnet J. Influenza Other Respi Viruses. 2022;16:906–915; Pastula ST et.al.,OFID, 2017,ofw270; Zhou JA et.al., CID, 2020, 70(5): 773-779; Disease Burden of Flu | CDC; Preliminary Medicare COVID-19 Data Snapshot (Dec 2021); ICER Report: Special Assessment of Outpatient Treatments for COVID-19 Feb 2022]
It's a huge market and with a clear unmet clinical need.
"we also know auto-abs play a role - but the only question that matters in both cases is: How Much ?" A lot I should think. Remember, the Universal study, seemingly as a conduit from Precision Medicine (which was a key focus of the last AGM presentation), had these aims:
Assessment of impact of risk factors for a poor outcome
− Autoantibodies against other type I IFNs (α and ω)
− Presence of naturally occurring antibodies against other type I IFNs associated with a poorer clinical outcome in patients with SARSCoV-2 and more recently flu infections
− Poor innate immune response
− Comparison of baseline immune (IFN) response versus viral load and outcome
Another day, another trip through Costas' fantastical financial fantasies.
So was that the RNS the inspired you to buy "500,000 shares"?
"It really is ridiculous to think we should use timelines from 10 years ago to guide our current expectations".
The lady doth protest too much me thinks...
Most definitely Delboy1977. Thanks for that reminder. Worth noting RM's words on announcement of the deal were; "AstraZeneca will be responsible for all future costs and early next year will kick off a Phase IIa study in patients with severe asthma". It took 2 years to quietly conclude commercial negotiations with AZ prior to P2, and that was not a timeline Synairgen would have been totally in control of either.